Introduction
Di abetes is a major cause of morbidity and mortality in the United States, resulting in substantial human and economic costs. [1] [2] [3] Diabetes management is complicated, requiring continuous patient involvement and the assistance of a team of health care professionals. 4, 5 Despite the availability of effective medications and evidence-based practice recommendations, 5, 6 most diabetes patients do not achieve therapeutic goals, and significant opportunities remain to improve diabetes management. [7] [8] [9] Moreover, broad variations persist in the quality of diabetes care across both health care providers and practice settings. 5 The chronic care model (CCM), 10 a multifaceted framework to redesign daily medical practices and enhance health care delivery, is used in many health care settings to guide systematic and individual improvements in chronic illness management, including diabetes. 4, [11] [12] [13] [14] The premise of the CCM is that quality care is not delivered in isolation but that each of the CCM elements works in tandem. 15 Six key elements are identified by the CCM, including four interdependent elements at the practice level (self-management support, decision support, delivery system design, and clinical information systems); a higher-level element (organizations of health care) at the health systems, which plays an overarching role in guiding practice-level development; and a broaderlevel element (linkages of resources and policies) at the community, which provides necessary resources and establishes policies linked to chronic illness care. 12, [15] [16] [17] [18] Previous studies show that CCM-based diabetes interventions improve patient outcomes, including better processes of care [e.g., diabetic foot examinations and glycated hemoglobin (A1C) checks] and intermediate outcomes (e.g., A1C, blood pressure, and lipids), reduced risk for cardiovascular events, and higher health status and health-related quality of life. 4, [11] [12] [13] [14] [15] [16] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] However, little is known about the cost-effectiveness of implementing the CCM for diabetes care.
Through its TRICARE program, the U.S. Department of Defense Military Health System (MHS) is one of the largest providers of health care in the United States, providing care to approximately 9.5 million beneficiaries at an annual cost of $48.5 billion (fiscal year 2010). 36 Diabetes is a critical issue for the MHS, with a prevalence of 5% among MHS enrollees and even greater prevalence rates in overweight (8-11%) and obese (16-37%) retirees and their dependents. [37] [38] [39] [40] [41] [42] The total annual cost of TRICARE beneficiaries aged 20-65 years with diagnosed diabetes was approximately $300 million in 2006; the average additional medical cost per beneficiary diagnosed with diabetes was $2150 annually. 43, 44 In an effort to improve outcomes and reduce costs associated with diabetes, the U.S. Air Force Wilford Hall Medical Center (WHMC) implemented the CCM in 2006 through the Diabetes Outreach Clinic (DOC), which restructured health care for diabetic beneficiaries by delivering services through a single, centralized location. Our analysis aimed to estimate costs, clinical outcomes, and cost-effectiveness of implementing the CCM for diabetes care in this military setting.
Methods

Diabetes Outreach Clinic at Wilford Hall Medical Center
The DOC operated during calendar years 2006-2008 at the WHMC. It was operating as a "one-stop shop" for diabetes patients, which allowed patients to obtain comprehensive care with one visit. The DOC staff consisted of an endocrinologist, a nurse practitioner, a counselor, an ophthalmologist, a dietitian, a certified diabetes educator, and support staff. Diabetes patients were seen for both diabetes-related treatments and routine primary care in the DOC.
The population for these analyses included individuals with an ICD-9-CM diagnosis of diabetes (250.xx) receiving care in the WHMC in the San Antonio area between January 2005 and December 2008. A total of 9654 diabetes patients, including 1171 DOC patients and 8483 usual care (UC) patients, from the military population health database were identified. Administrative data included demographics, clinical data (e.g., A1C, blood pressure, and lipids), medical utilization (e.g., primary and specialty care visits), and pharmacy records. For DOC patients, we defined the records from 1 year prior to DOC entry as pre-DOC data (or baseline) and all records after DOC entry as post-DOC data (or follow-up); for UC patients, we defined the records from 1 year prior to January 2006 (i.e., DOC starting date) as baseline data and all records after that time as follow-up data. A total of 249 patients less than 18 years of age were excluded, and thus the study cohort in this analysis comprised 9405 diabetes
Framework of a Markov Decision Model
Using TreeAge Pro Suite 2009 (TreeAge Software, Williamstown, MA), we modified a prior Markov decision model 45 to estimate the incremental cost-effectiveness of the DOC compared with UC. The model directly incorporated intervention costs and effectiveness from military data to estimate life expectancy, quality-adjusted life-expectancy [expressed as quality-adjusted life-years (QALYs)], clinical outcomes, as well as direct medical and nonmedical costs associated with the DOC and UC. Our base case model examined 50-year-olds with type 2 diabetes who participated in the DOC or UC in yearly cycles over a 20-year time horizon from the health care system perspective. Future costs and benefits were discounted at 3% annually, 46 and the U.S. Consumer Price Index 47 was used to convert all monetary costs to 2010 U.S. dollars.
Basic Model Structure
The model is illustrated in Figure 1 , which describes the progression of disease through microvascular complications, macrovascular complications, and mortality. In this model, all patients were assumed to have uncomplicated diabetes at the start of the model. Over time, diabetes could progress to microvascular complications (including retinopathy, nephropathy, or neuropathy), macrovascular complications (including coronary heart disease or stroke), or both. Complications were assumed to be irreversible. To be conservative, the DOC and UC were assumed to have identical effects on the progression of disease in patients who already had diabetes complications, thus implying that the model only examined differences between strategies in the development of complications.
In the model, cost-effectiveness was estimated over a 20-year period following the intervention period, assuming that treatments continued for the duration. The United Kingdom Prospective Diabetes Study (UKPDS) risk equations were applied to predict treatment effects, i.e., long-term probabilities of developing microvascular [48] [49] [50] and macrovascular [51] [52] [53] complications, using empirical, post-intervention demographic and clinical data in those diabetes patients who were alive and without diabetes complications at the date (i.e., December 2008) when the DOC closed operation. Among 9405 diabetes patients, 1417 diabetes patients who fulfilled these criteria were identified (196 DOC and 1221 UC patients; 
Appendix 2)
. The parameters applied in the UKPDS risk equations and the Markov decision model are summarized in Table 1 . Given significant differences in parameter values between groups (Appendix 2), Table 1 contains values adjusted for all known demographic and clinical characteristics that differed between groups at baseline. Model assumptions are listed in the footnotes for Table 1 ; in the base case analysis, based on our data characteristics, we assumed a cohort with a mean age of 50 years, white race, nonsmoking status, mean diabetes duration of 5 years, and other patient parameters as listed in Table 1 . Tables 2 and 3 and Appendixes 3-7. Probabilities of death and of microvascular or macrovascular complications were predicted using the UKPDS risk equations and/or derived from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation study 54 (Appendixes 3-6).
Model input parameters are shown in
Annual direct medical costs related to health care providers, laboratory tests, physician office visits, diabetes complications, death, and medications were included in the model ( Table 2 and Appendix 7). Indirect costs were not included, assuming their capture in the assessment of QALYs, per the recommendation of the Panel on Cost-Effectiveness in Health and Medicine. 46 Medicare reimbursement data were used to estimate costs of laboratory tests (A1C and lipid panel) and physician office visits. 55 Hourly wage costs for health care providers in both the DOC and UC were based on National The mean value of each clinical data was adjusted for age at study entry, A1C at baseline, and gender. c The mean age of 50 years was from all 1417 diabetes patients surviving without any diabetes complications at the date (i.e., December 2008) when the DOC closed operation, and this age was also used as the starting age for both the DOC and the UC cohort in the model. d White population was assumed for base case analysis. e The most current post-study data (mean weight, height, and BMI) from 1417 patients were used in the model. f Patients were assumed to be nonsmokers (since less than 10% of our population was the current smoker) for the base case analysis. g Patients were assumed to have creatinine clearance <100 ml/min for base case analysis. h Patients were assumed to have no atrial fibrillation [because no DOC patients had atrial fibrillation and only 15 (1.2%) UC patients had atrial fibrillation] for base case analysis. i Patients had no macroalbuminuria for base case analysis. j Patients had no microalbuminuria for base case analysis. k The mean duration of diabetes for patients was assumed to be 5 years. l The mean numbers were used for base case analysis. Uniform (a to b) = uniform distribution (minimum to maximum); triangular (a to b) = triangular distribution (minimum to maximum); log normal (a to b) = log normal distribution (95% confidence interval).
Occupational Employment and Wage Estimates. 47 One-time and annual costs of diabetes complications, one-time costs of death, as well as medication costs for diabetes, hypertension, and cholesterol control were based on data from the models developed by the Centers for Disease Control and Prevention and Research Triangle Institute International. 56 In analyses from the societal perspective, both direct medical and nonmedical costs were included. Direct nonmedical costs included patient time and monetary costs for physician office visits and diabetes education classes/ visits ( Table 2) . Patient time costs for time missed from work or school to receive care and for time donated by others (e.g., for rides or babysitting) to allow care to occur were quantified based on DOC data or published literature 57 and then valued according to the average hourly wage of a U.S. nonfarm production worker 47 and the average annual frequency of visits and classes as measured in DOC data. In addition, monetary costs to the patient for expenses such as transportation, parking, and babysitting or childcare were estimated from published literature 57 and then valued based on the average annual frequency of visits and classes as derived from DOC data.
Health utilities are a measure of health-related quality of life, with perfect health = 1 and death = 0. In a cost-effectiveness analysis, this utility weight for each health state is multiplied by time in that state. As an individual's health changes over time, these products are summed to represent the total number of QALYs. 46 To estimate health utilities associated with type 2 diabetes with or without complications, an additive prediction model was applied to estimate health utilities according to demographic, treatment, and complication variables. 58 The baseline health utility of 0.689 depicts a nonobese man with type 2 diabetes who is treated with diet and exercise and has no cardiovascular risk factors nor any microvascular, neuropathic, or cardiovascular complications ( Table 3) .
Sensitivity Analyses
One-way sensitivity analyses were conducted for model parameters (Appendix 5 and Tables 2 and 3) to assess the effect of varying parameter estimates within clinically plausible ranges and identify parameters whose variation changed the base case incremental cost-effectiveness ratio (ICER) >20%. Next, the ICER was recalculated using the societal perspective instead of the health care system perspective. Finally, the original assumption that all DOC and UC patients had uncomplicated diabetes at the start of the model was tested by changing initial proportions of patients in health states to mirror the DOC cohort and then the UC cohort, recalculating cost-effectiveness for each starting cohort from the societal perspective.
A probabilistic sensitivity analysis was performed from the health care system perspective, where model parameters were simultaneously varied over distributions. 59 Distributions for parameters were chosen to reflect the level of certainty and the characteristics of the parameter range: beta distribution was assigned for probabilities; uniform, triangular, or log normal distributions for costs; and normal or uniform distributions for utilities. A value from each parameter's probability distribution was randomly selected during each of 10,000 Monte Carlo iterations, and then these values were used to compute the cost-effectiveness among strategies of being studied for each iteration. The cost-effectiveness acceptability curve 60 was used to summarize results, showing the likelihood that a given strategy would be favored for a given acceptability threshold, which is defined as the maximum amount that society is willing to pay for an incremental gain in health.
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Results
Over the study period, DOC patients had better glycemic control (from 7.8% to 7.2% vs from 6.8% to 7.0%) and dyslipidemic control (total cholesterol, 173 vs 184 mg/dl; low-density lipoprotein cholesterol, 93 vs 102 mg/dl), fewer annual primary care visits (2.0 vs 3.0), and more annual A1C (2.2 vs 1.7) and lipids (1.7 vs 1.4) checks compared with UC patients. Appendices 1 and 2 summarize the observed demographic, clinical, and medical utilization characteristics at baseline and follow-up. Base Case Analysis a The ICER of cost per QALY was calculated from the societal perspective. b Initial proportions of patients in 5 health states at the start of the model were changed to mirror the DOC cohort, and then the ICER of cost per QALY was calculated from the societal perspective. c Initial proportions of patients in 5 health states at the start of the model were changed to mirror the UC cohort, and then the ICER of cost per QALY was calculated from the societal perspective. Figure 2 shows the results of one-way sensitivity analyses, where six parameters whose variations changed the base case ICER >20% were identified. Of these, only the yearly cost for specialty care visits in DOC patients could drive the ICER >$100,000/QALY. Variation of parameters not shown in Figure 2 did not increase the ICER above $50,000/QALY. Analysis from the societal perspective showed that the DOC cost $4909 more than UC and gained 0.117 QALYs, resulting in an ICER of $42,051/QALY over 20 years (Table 4) . Changing the initial proportion of cohorts in the five health states at the start of model to mirror the complication rates of DOC patients and then again of UC patients resulted in ICERs of $61,243/ QALY and $61,813/QALY, respectively, from the societal perspective (Table 4) .
Sensitivity Analyses
When parameters were simultaneously varied over the distributions in the probabilistic sensitivity analysis, the DOC was more likely to be favored with an acceptability threshold >$48,000/QALY (Figure 3) . In addition, at a threshold of $50,000/QALY, the DOC was favored in 51% of model iterations; at $100,000/QALY, the DOC was favored in 72%.
from a health care system perspective over 20 years, the CCM strategy performed through the DOC in a military-based setting was quite cost-effective, costing approximately $45,500/QALY. From a societal perspective, it was even more favorable, with an ICER less than $42,100/QALY.
Diabetes care involves complex interactions among patients, physicians, health care systems, and society as a whole, with barriers occurring at every level. 11 A major contributor to suboptimal diabetes care is a delivery system that too often is fragmented, lacks clinical information capabilities, duplicates services, and is poorly designed for the delivery of chronic care. 5 The American Diabetes Association suggests that the CCM may be well-suited to the management of diabetes because it addresses these complex issues, redefines the role of providers, and promotes patient self-management. 5, 14 Moreover, our analyses showed that patients in the DOC had a lower number of visits for primary or specialty care (Table 1 ) and that total annual cost for primary or specialty care visits, compared with other model parameters, influenced more the cost-effectiveness of the DOC (Figure 2) , which may suggest that centralizing the patient's care by the DOC combined with the CCM potentially eliminated the need for multiple visits.
Knowledge on CCM cost-effectiveness in diabetes care is nascent; 14 more research is needed to understand the costs and benefits to practices, payers, and patients. Studies are available to document cost-consequence or cost-effectiveness results related to various potential components of the CCM, 14, 32 but the cost-effectiveness analysis of the CCM as a whole may not be well-known. We found only one full economic evaluation 62 published by Huang and colleagues, 63 comparing CCM implementation costs with the benefits of improved health outcomes in diabetes patients in U.S. federally qualified community health centers. In that study, CCM reduced lifetime risks of blindness, end-stage renal disease, and coronary artery disease, resulting in an increase in benefits at a cost of $33,386/QALY. Compared with that study, our estimate of CCM cost-effectiveness over 20 years from the societal perspective, $42,051/QALY, is higher. This discrepancy is likely due to a number of differences in models; for instance, our patient cohort was a military population, younger (50 vs 55 years), less racially diverse, and transitioned through a model where some assumptions were made to bias against the CCM effect (discussed later). Furthermore, we used costs in 2010 U.S. dollars rather than 2004 U.S. dollars and included data from a two-group effectiveness study rather than pre-and post- 
Willingness to pay (cost per QALY)
Discussion
The CCM is a multifaceted intervention intended to provide effective and comprehensive care for diabetes and other chronic conditions. Although transformation of health care organizations using the CCM must expend considerable resources, in theory, their expenditures will be offset downstream with the delay or elimination of diabetes-related complications. In this regard, costeffectiveness analysis from a health care system perspective may be particularly compelling. Our study showed that, comparisons. Despite these differences, both studies found that implementation of the CCM was economically reasonable and consistent with accepted societal costeffectiveness thresholds. 64 Cost-saving medical interventions are rare. Most new diabetes treatment strategies are more effective but also more costly, requiring incremental resources per QALY gained. 65 There is no absolute cost-effectiveness threshold, and the long-cited benchmark from the literature of $50,000/QALY is unsupported. 64, 66 One analysis 66 argues that a more plausible threshold of society's willingness to pay for modern health care ranges between $100,000 and $300,000 per QALY, which is substantially higher than the traditional threshold.
Health care costs in the United States are increasing unsustainably, and efforts to control expenditures should focus on the value of health care interventions, reflecting health benefits that justify their costs. 67 High-cost interventions may provide good value when they are highly beneficial. The ICER estimates the additional cost required to obtain additional health benefits and provides a key measure of the value of a health care intervention. 67 Based on our analysis, the CCM strategy through the DOC in a military-based setting appears to be a goodvalue care for diabetes, but unfortunately, further data on the DOC do not exist since it was closed in 2009 because of military priority considerations. We recognize that the cost-effectiveness of an intervention should not solely determine its application; at the same time, however, cost-effectiveness should be one of several factors when considering the delivery of high-value, cost-conscious health care. 67 Furthermore, the goal of policy should be to preserve the delivery of interventions that do have good value. 68 As with all modeling efforts, 69 the computational model developed here has several limitations. First, interpretations of study results are contingent on data quality and model assumptions. Second, subjects in this analysis were representative of the diabetes population in a military community, although they may not be fully generalizable to other populations or health care settings. Third, our effectiveness data were not from a randomized controlled trial, resulting in differences in baseline characteristics between the DOC and UC. For instance, we cannot directly apply the unadjusted follow-up A1C in the UKPDS risk equations to predict probabilities of developing microvascular and macrovascular complications. Instead, we used the adjusted follow-up A1C, which was adjusted for all known demographic (i.e., age at baseline and gender) and clinical characteristics (baseline A1C) that differed significantly between two groups at baseline (Appendix 2). Fourth, the A1C per se or the change in mean A1C per se was not directly considered a model parameter. However, the baseline A1C and the change in mean A1C were considered when the adjusted mean post-intervention A1C was estimated for predicting probabilities of developing microvascular and macrovascular complications using UKPDS risk equations. As such, our current model cannot address how much reduction in A1C needs to be realized by the DOC in order to achieve a given cost-effectiveness threshold. Fifth, assuming an identical risk of disease progression for DOC and UC patients with diabetes complications was a conservative strategy. This is because if, instead, the DOC combined with the CCM strategy has intervention effects on disease progression in the patients who already had diabetes complications, then this assumption potentially biases the model against the DOC effect. Sixth, because there is no empirical utility data, we applied the same literature-based utility weights to both strategies, which again may underestimate the CCM's potential to improve quality of life. 13, 34, 35 Lastly, our base case analysis was assumed to model the cost-effectiveness over a 20-year time frame; however, the base case ICERs over shorter time horizons, e.g., at 5 years ($189,138/QALY) and 10 years ($87,092/QALY), are still below the currently suggested cost-effectiveness thresholds for modern health care.
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Conclusions
Status quo is not an option; reforms at the delivery system level are imperative to address significant lapses in quality of care as well as the high and rapidly increasing cost of care. 70, 71 One potentially important tool for slowing the growth of health care expenditures is reliable information regarding the cost-effectiveness of alternative interventions.
Information on the cost-effectiveness of implementing the CCM strategy for diabetes care is just beginning to emerge, and our study adds evidence to document that, compared with UC, the CCM strategy provides greater health benefits at an attractive cost. From the perspective of a health care system or society, the CCM strategy provides good value. When the CCM strategy is used for diabetes care in the military-based setting, not only is it effective in improving patient outcomes, but it is also an economically reasonable, promising investment.
